Clearside Biomedical Receiveable Turnover 2015-2025 | CLSD

Clearside Biomedical receiveable turnover from 2015 to 2025. Receiveable turnover can be defined as an accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts.

Clearside Biomedical Receiveable Turnover 2015-2025 | CLSD

Clearside Biomedical receiveable turnover from 2015 to 2025. Receiveable turnover can be defined as an accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$246.7B
Amgen (AMGN)$159.1B
Gilead Sciences (GILD)$146.4B
Vertex Pharmaceuticals (VRTX)$100.2B
Bristol Myers Squibb (BMY)$98.4B
GSK (GSK)$80.7B
CSL (CSLLY)$70.8B
Regeneron Pharmaceuticals (REGN)$60.6B
Alnylam Pharmaceuticals (ALNY)$60.1B
Argenex SE (ARGX)$40.2B
Insmed (INSM)$26.9B
BioNTech SE (BNTX)$26.8B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20.4B
Incyte (INCY)$16.7B
Illumina (ILMN)$15.6B
Genmab (GNMSF)$15.3B
Genmab (GMAB)$15.3B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$10.9B
Moderna (MRNA)$10.9B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Exelixis (EXEL)$10.1B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.6B
Bio-Techne Corp (TECH)$8.6B
Blueprint Medicines (BPMC)$8.3B
Halozyme Therapeutics (HALO)$8.2B
Roivant Sciences (ROIV)$8B